The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi z dodatnim markerem HER2
- •Zaawansowana choroba (stadium IV)
- •Leczenie lekiem T-Dxd
- •Dostępne próbki tkanki z archiwum
✗ Disqualifies
- •Rak piersi potrójnie ujemny (TNBC)
- •Rak piersi receptorowo dodatni
- •Brak dostępnych próbek tkanki z archiwum
- •Leczenie innymi lekami niż T-Dxd
Simplified criteria — AI translation
Trial details
- Last updated (source)
- March 26, 2024
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Ji-Yeon Kim
Seoul, South Korea
Trial contact
Ji-Yeon Kim
MIRYOUNG HONG
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.